Therapy Areas: Central Nervous System
Alpha Cognition Touts Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment
13 June 2022 - - Canada-based biopharmaceutical company Alpha Cognition Inc. (TSX Venture: ACOG) (OTCQB: ACOGF) has discovered two GEM combinations, ALPHA-0702 and ALPHA-0802, and positive preclinical data from each candidate therapy, the company said.

ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from full length progranulin which have therapeutic potential across multiple neurodegenerative diseases.

GEMs have been shown to be important in regulating cell growth, survival, repair, and inflammation.

ALPHA-0702 and ALPHA-0802 have demonstrated robust results in a recent preclinical study, leading the company to believe in the future potential of this platform to develop therapeutics to treat a wide array of diseases.

These data underscore robust preclinical evidence supporting Alpha Cognition's approach to treating neurodegenerative disease and highlight the company's strategy to validate these data in additional pre-clinical studies.

Highlights of the positive proof of concept pre-clinical results demonstrated with ALPHA-0702, ALPHA-0802, and ALPHA-0602 include:

ALPHA-0702 and ALPHA-0802 maintained prolonged cell survival and neuronal morphology, with a potency equivalent to, or approaching full length progranulin.

ALPHA-0702 and ALPHA-0802 reduced both mutant and wild type TDP-43 toxicity, with a potency equivalent to, or approaching full length progranulin.

ALPHA-0602, and both ALPHA-0702 and ALPHA-0802 enhanced Cathepsin D maturation suggestive of improved lysosomal function.

These effects were seen in induced pluripotent stem cells, derived from patients harboring toxic TDP-43 mutations, that were terminally differentiated into motor neurons.

Both therapeutic candidates have the potential to be as effective as full-length progranulin in promoting Cathepsin D maturation, where under conditions of neuronal stress (FTD models) progranulin has been shown to be inappropriately processed.

Ongoing studies will confirm reduced neuroinflammation and toxicity associated with ALPHA compounds.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Amyotrophic Lateral Sclerosis, for which there are limited treatment options.

ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects.

ALPHA-1062's active metabolites is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.

ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and as an intranasal formulation for traumatic brain injury.

ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, promotes cell survival, regulates certain inflammatory processes, and plays a significant role in regulating lysosomal function and microglial responses to disease.


Related Headlines